HYVET: landmark trial voted 2008 Trial of the Year by the ImpACT/Society for Clinical Trials and the American Heart Association
References
1. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
2. United Nations. World population ageing 1950-2050. IV. Demographic profile of the older population. Available from http://www.un.org/esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf.
3. Leonetti G, Emeriau J-P, Knauf H et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005; 21: 37-46.
4. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7: 683-9.
5. American Heart Association. News release. Top research advances include studies that influence medical care, apply science to «real world» communities. January 21, 2009. Available from http://americanheart.mediaroom.com/index.php?s=43&item=648.
6. Medscape Cardiology. This Year's Awards for the Most Important Trials Go to... HYVET and ACCOMPLISH. March 2, 2009. Available from http://cme.medscape.com/viewarticle/588818.
7. Faculty of 1000 Medicine. All time Top 10 by F1000 factor. All of Medicine. March 30, 2009. Available from http://www.f1000medicine.com/top10/ classics/.
8. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety 2001; 24: 1155-65.
Review
For citations:
Article E. HYVET: landmark trial voted 2008 Trial of the Year by the ImpACT/Society for Clinical Trials and the American Heart Association. Systemic Hypertension. 2009;(2):44-45.
Email this article 